Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine
| Autor: | Fazel, F. S., Haddadi, M., Khoshnevisan, A., Samad Muhammadnejad, Muhammadnejad, A., Mazaheri, Z., Arjomandnejad, M., Shirkoohi, R., Oghabian, M. -A, Sherkat-Khameneh, N., Amanpour, S., Kazemimanesh, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Glioblastomamultiform In vitro chemosensitivity and resistance assay Personalized medicine Primary explant technique Stereotactic biopsy
Stereotactic biopsy lcsh:R Primary explant technique lcsh:Medicine Glioblastomamultiform In vitro chemosensitivity and resistance assay Personalized medicine Article |
| Zdroj: | Iranian Journal of Basic Medical Sciences Scopus-Elsevier Iranian Journal of Basic Medical Sciences, Vol 17, Iss 11, Pp 922-925 (2014) |
| ISSN: | 2008-3874 2008-3866 |
| Popis: | Objective(s):P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. Materials and Methods: Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay[AGA1] . Results: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods. Conclusion: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|